Open AccessOral Delivery of Pterostilbene by L-Arginine-Mediated “Nano-Bomb” Carrier for the Treatment of Ulcerative Colitis
Author(s) -
Wei Wei,
Yujie Zhang,
Runqing Li,
Yameng Cao,
Xiangji Yan,
Yana Ma,
Yuanyuan Zhang,
Mei Yang,
Mingzhen Zhang
Publication year - 2022
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s347506
Subject(s) - pharmacology , ulcerative colitis , inflammatory bowel disease , bioavailability , drug delivery , proinflammatory cytokine , drug carrier , colitis , medicine , curcumin , oral administration , chitosan , drug , chemistry , inflammation , immunology , biochemistry , disease , organic chemistry
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) of unknown aetiology affecting the colon and rectum. Pterostilbene (PS) has been reported as an effective antioxidant and anti-inflammatory agent in preclinical IBD models. However, the therapeutic outcomes of PS are limited by potential side effects associated with the systemic exposure and the modest bioavailability afforded by its oral administration. These issues can be improved with the use of intelligent responsive nanoparticles with the ability of lysosome escape, given their high drug delivery capacity and reducing the side effects.